<--- Back to Details
First PageDocument Content
Oncology / Bendamustine / Ofatumumab / Alemtuzumab / Leukemia / Rituximab / Fludarabine / Placebo / Chemotherapy / Medicine / Lymphocytic leukemia / B-cell chronic lymphocytic leukemia
Oncology
Bendamustine
Ofatumumab
Alemtuzumab
Leukemia
Rituximab
Fludarabine
Placebo
Chemotherapy
Medicine
Lymphocytic leukemia
B-cell chronic lymphocytic leukemia

idelalisib 100mg and 150mg tablets (Zydelig®) Gilead Sciences Ltd. SMC No[removed]February 2015

Add to Reading List

Source URL: www.scottishmedicines.org.uk

Download Document from Source Website

File Size: 219,51 KB

Share Document on Facebook

Similar Documents

Allogeneic hematopoietic SCT for patients with autoimmune diseases

Allogeneic hematopoietic SCT for patients with autoimmune diseases

DocID: 1pQwt - View Document

administration of cytoxan cytoxan dose for breast cancer, fludarabine and cytoxan and follicular lymphoma busulfan cytoxan vp16. cytoxan teatment for dry eyes uric counts cytoxan, infusion rate for cytoxan. cytoxan predn

administration of cytoxan cytoxan dose for breast cancer, fludarabine and cytoxan and follicular lymphoma busulfan cytoxan vp16. cytoxan teatment for dry eyes uric counts cytoxan, infusion rate for cytoxan. cytoxan predn

DocID: 1fKBX - View Document

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid

DocID: 1fBTU - View Document

CIBMTR 2015 New Working Committee Studies Working Committee Study #  Title

CIBMTR 2015 New Working Committee Studies Working Committee Study # Title

DocID: 1a43D - View Document

Microsoft Word - Roche 5-10 obinutuzumabPSD final.docx

Microsoft Word - Roche 5-10 obinutuzumabPSD final.docx

DocID: 12vwe - View Document